One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
Carl Johan Malm, MD, PhD a,b , Joakim Alfredsson, MD, PhD c,d , David Erlinge, MD, PhD e , Tomas Gudbjartsson, MD, PhD f,g , Jarmo Gunn, MD, PhD h , Stefan James, MD, PhD i , Christian H. Møller, MD, PhD j,k , Susanne J. Nielsen, RN, PhD a,b , Ulrik Sartipy, MD, PhD l,m , Theis Tønnessen, MD, PhD n,o , and Anders Jeppsson, MD, PhD a,b Gothenburg, Sweden; Linkoping, Sweden; Lund, Sweden; Reykjavik, Iceland; Turku, Finland; Uppsala, Sweden; Copenhagen, Denmark; Stockholm, Sweden; Oslo, Norway
doi : 10.1016/j.ahj.2023.01.011
Volume 259, May 2023, Pages 1-8
The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome.
Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study
C. Michael Gibson, MD a , Steven Steinhubl, MD b , Dhanunjaya Lakkireddy, MD c , Mintu P. Turakhia, MD, MAS d,e , Rod Passman, MD, MSCE f , W. Schuyler Jones, MD g , T. Jared Bunch, MD h , Anne B. Curtis, MD i , Eric D. Peterson, MD, MPH g , Jeremy Ruskin, MD j , Leslie Saxon, MD k , Michael Tarino, MBA l , Khaldoun G. Tarakji, MD, MPH m , Nassir Marrouche, MD n , Mithun Patel, MD o , Ante Harxhi, MD p , Simrati Kaul, PhD p , Janeta Nikolovski, PhD q , Stephanie Juan, MPH p , Kevin Wildenhaus, PhD q , C.V. Damaraju, PhD q , and John A. Spertus, MD, MPH r , the Heartline Steering Committee Boston, MA; La Jolla, CA; Overland Park, KS; Stanford, CA; Palo Alto, CA; Chicago, IL; Durham, NC; Salt Lake City, UT; Salt Lake City, UT; Buffalo, NY; Los Angeles, CA; Union, WA; Mounds View, MN; New Orleans, LA; Cupertino, CA; Titusville, NJ; Raritan NJ; Kansas City, MO
doi : 10.1016/j.ahj.2023.01.004
Volume 259, May 2023, Pages 30-41
The impact of using direct-to-consumer wearable devices as a means to timely detect atrial fibrillation (AF) and to improve clinical outcomes is unknown.
A Randomized Trial of Lenient Versus Strict Arm Instruction Post Cardiac Device Surgery (LENIENT)
Mehrdad Golian, MD, Mouhannad M. Sadek, MD, Alper Aydin, MD, Darryl Davis, MD, Martin Green, MD, Andres Klein, MD, Girish M. Nair, MBBS, MSc, Pablo Nery, MD, F. Daniel Ramirez, MD, Calum Redpath, MBChB, PhD, Simon P. Hansom, MBChB, MD, George A. Wells, PhD, and David H. Birnie, MBChB, MD Ontario, Canada
doi : 10.1016/j.ahj.2023.01.016
Volume 259, May 2023, Pages 52-57
Design and rationale of re-energize fontan: Randomized exercise intervention designed to maximize fitness in fontan patients
Elif Seda Selamet Tierney, MD 1 , Latha Palaniappan, MDMS, 2 , Mary Leonard, MD MSCE, 3 , Jin Long, PhD, 3 , Jonathan Myers, PhD, 4 , Tania Dávila, BA, 1 , Mavis C. Lui, BS, 1 , Feliks Kogan, PhD, 5 , Inger Olson, MD, 1 , Rajesh Punn, MD, 1 , Manisha Desai, PhD, 6 , Lauren M. Schneider, PsyD, 7 , Chih-Hung Wang, MD, 8 , John P. Cooke, MDPhD, 9 , and Daniel Bernstein, MD 1 United States
doi : 10.1016/j.ahj.2023.02.006
Volume 259, May 2023, Pages 68-78
Rationale and design of the colchicine for the prevention of perioperative atrial fibrillation in patients undergoing major noncardiac thoracic surgery (COP-AF) trial
David Conen, MD MPH, 1,2,3 , Ekaterine Popova, MD, 4,5 , Michael Ke Wang, MD, 1,2,3 , Matthew T.V. Chan, MBBS MMed PhD, 6 , Giovanni Landoni, MD, 7,8 , Cara Reimer, MD MSc, 9 , Sadeesh K. Srinathan, MD MSc, 10 , Juan P. Cata, MD, 11 , Sean R. McLean, MD, 12,13 , Juan Carlos Trujillo Reyes, MD PhD, 14 , Ascensión MartÃn Grande, MD, 15 , Anna Gonzalez Tallada, MD PhD, 16 , Daniel I. Sessler, MD, 17 , Edith Fleischmann, MD, 18 , Donna E. Maziak, MDCM MSc, 19 , Barbara Kabon, MD, 18 , Luca Voltolini, MD PhD, 20 , Laura Gutiérrez-Soriano, MD, 21 , Vikas Tandon, MD, 2 , Deborah DuMerton, RN, 9 , Biniam Kidane, MD MSc, 22 , Ravi Rajaram, MD MSc, 23 , Yaron Shargall, MD, 24 , John D. Neary, MD, 2 , Jennifer R. Wells, MSc, 1 , William F. McIntyre, MD PhD, 1,2,3 , Steffen Blum, MD PhD, 1,25 , Sandra N. Ofori, MBBS MSc, 1,2,26 , Jessica Vincent, MSc, 1 , Lizhen Xu, PhD, 1,2 , Zhuoru Li, MSc, 1 , Jeff S. Healey, MD MSc, 1,2,3 , Amit X. Garg, MD PhD, 1,3,27 , and PJ Devereaux, MD PhD 1,2,3 , on behalf of the COP-AF Investigators†Ontario, Canada; Barcelona, Spain
doi : 10.1016/j.ahj.2023.01.018
Volume 259, May 2023, Pages 87-96
Long-term incidence of infective endocarditis among patients with congenital heart disease
Eva Havers-Borgersen, MD a , Jawad H. Butt, MD a , Lauge Østergaard, MD, PhD a , Jeppe K. Petersen, MB a , Christian Torp-Pedersen, MD, DMSc b , Lars Køber, MD, DMSc a , and Emil L. Fosbøl, MD, PhD a Copenhagen, Denmark; Hillerod, Denmark
doi : 10.1016/j.ahj.2023.01.012
Volume 259, May 2023, Pages 9-20
A U-shaped association between dietary phosphorus intake and new-onset hypertension: a nationwide cohort study in China
Qimeng Wu, MD a , Ziliang Ye, MD a , Chun Zhou, MD a , Mengyi Liu, MD a , Yuanyuan Zhang, MD a , Zhuxian Zhang, MD a , Panpan He, MD a , Rui Li, MS b,c , Huan Li, MD a , Sisi Yang, MD a , Yanjun Zhang, MD a , Jianping Jiang, MD a , Jing Nie, MD a , Chengzhang Liu, MS a,b,c,1 , and Xianhui Qin, MD a,b,c,1 Guangzhou, China; Hefei, China
doi : 10.1016/j.ahj.2023.01.013
Volume 259, May 2023, Pages 21-29
Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction
Jonas Faxén, MD PhD a,b,c , Lina Benson, MSc d , Ängla Mantel, MD PhD e,f , Gianluigi Savarese, MD PhD b,d , Camilla Hage, RN PhD b,d , Ulf Dahlström, MD PhD g , Johan Askling, MD PhD e,h , Lars H. Lund, MD PhD b,d , and Daniel C. Andersson, MD PhD b,c Stockholm, Sweden; Linkoping, Sweden
doi : 10.1016/j.ahj.2023.02.001
Volume 259, May 2023, Pages 42-51
Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial
Soohyung Park, MD 1 , Seung-Woon Rha, MD, PhD 1,2 , Byoung Geol Choi, PhD 2 , Jang Hyun Cho, MD, PhD 3 , Sang Ho Park, MD, PhD 4 , Jin Bae Lee, MD, PhD 5 , Yong Hoon Kim, MD, PhD 6 , Sang Min Park, MD, PhD 7 , Jae Woong Choi, MD, PhD 7 , Ji Young Park, MD, PhD 7 , Eun-Seok Shin, MD, PhD 8 , Jae Beom Lee, MD 9 , Jon Suh, MD, PhD 10 , Jei Keon Chae, MD, PhD 11 , Young Jin Choi, MD, PhD 12 , Myung Ho Jeong, MD, PhD 13 , Kwang soo Cha, MD, PhD 14 , Seung Wook Lee, MD, PhD 15 , Ung Kim, MD, PhD 16 , Gi Chang Kim, MD, PhD 17 , Woong-Gil Choi, MD, PhD 18 , Yun-Hyeong Cho, MD, PhD 19 , Deok-kyu Cho, MD, PhD 20 , Jihun Ahn, MD, PhD 21 , Soon-Yong Suh, MD, PhD 22 , Se Yeon Choi, PhD 2 , Jae Kyeong Byun, PhD 2 , Jin Ah Cha, BS 2 , Soo Jin Hyun, BS 2 , Ji Bak Kim, MD, PhD 1 , Cheol Ung Choi, MD, PhD 1 , and Chang Gyu Park, MD, PhD 1 Seoul, Korea; Suncheon, Korea; Cheonan, Korea; Daegu, Korea; Chuncheon, Korea; Seoul, korea; Ulsan, Korea; Anyang, Korea; Bucheon, Korea; and Jeonju, Korea
doi : 10.1016/j.ahj.2023.01.020
Volume 259, May 2023, Pages 58-67
Microvascular obstruction identifies a subgroup of patients who benefit from stem cell therapy following ST-elevation myocardial infarction
Sarah J. Davidson, BS a,^,# , Jerome Roncalli, MDPhD b,^,# , Daniel Surder, MD c,^,# , Roberto Corti, MD c,^,# , Atul R. Chugh, MD d,^,# , Phillip C. Yang, MD e,^,# , Timothy D. Henry, MD f,^,# , Larissa Stanberry, PhD g,^,# , Patricia Lemarchand, MDPhD h,^,# , Jeau-Paul Beregi, MD i,^,# , and Jay H. Traverse, MD g,j,^,# Durham, NC; Zurich, Switzerland; Indianapolis, IN; Palo Alto, CA; Cincinnati, OH; Minneapolis, OH; Nantes, France; Nimes, France; Minneapolis, MN
doi : 10.1016/j.ahj.2023.02.004
Volume 259, May 2023, Pages 79-86
Microvascular obstruction (MVO) is associated with greater infarct size, adverse left-ventricular (LV) remodeling and reduced ejection fraction following ST-elevation myocardial infarction (STEMI).
